학술논문
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
Document Type
article
Author
Source
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Subject
Language
English
ISSN
2051-1426